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Malignant melanomas are capable of producing a wide range 
of cytokines with multiple biologic functions, including in-
terleukin 6 (IL-6). We have observed an inverse relationship 
between IL-6 production of three B 16-derived murine mela-
noma cell lines (NP133, HFH18, and HFH(M)) and the 
tumorigenicity of these melanoma cells in syngeneic mice. 
To further test the effect of IL-6 on melanoma growth, a 
non - IL-6 - producing murine B 16-derived melanoma cell 
line (HFH18) was transfected with a murine IL-6 expression 
vector, resulting in stable transfectants (HFH18/ IL-6(+») that 
expressed significant amounts of IL-6 mRNA and secreted 
high levels of bioactive IL-6. Syngeneic C57BL/ 6 mice in-
oculated subcutaneously with HFH18/ IL-6(+) cells devel-
oped tumors that reached a final mean diameter of less than 
half the size of tumors that developed in mice inoculated 
with either HFH18 parental or HFH18 cells transfected 
with the IL-6 eDNA in the non-coding 3'-5' orientation 
(HFH18/IL-6(-) cells). In addition, mice bearing IL-6-
M alignant melanoma is a serious neoplasm that ac-counts for 1-2% of cancer deaths per year in the United States. The incidence of malignant mela-noma is increasing more rapidly than that of any other cancer, at the rate of 4% per year, with 
32,000 new cases of melanoma expected this year [1]. Early diagno-
sis and surgical excision of thin primary cutaneous melanoma suc-
cessfully prevent metastatic progression. However, the response 
rates of patients with advanced metastatic disease remain low to 
both standard chemotherapy and immunologically based therapy 
strategies. Further understanding of the biologic behavior of mela-
noma cells is necessary to devise more successful treatment ap-
proaches for these patients. 
The role of cytokines and growth factors in the development and 
progression of cancer has recently become an active area of cancer 
research . Melanomas are capable of producing a number of cyto-
kines with multiple biologic functions, including interleukin 6 (IL-
6) [2-8]. The heterogeneity of cytokine production among mela-
nomas and the ability of individual human melanomas to produce 
multiple cytokines have been recently demonstrated by our group 
and others [5,9]. In particular, we have shown that the cytokine 
profile of two widely used, distinct human melanoma cell lines, 
A375 and G361, demonstrate marked differences in IL-6 produc-
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producing HFH18/ IL-6(+) tumors survived twice as long as 
mice bearing HFH18 parental or HFH18/ IL-6H tumors. 
The specificity of melanoma growth inhibition by IL-6 was 
confirmed by the reversal of the slow-growing phenotype of 
HFH18/ IL-6(+) cells by local peri tumoral administration of 
neutralizing a-murine IL-6 antibody. IL-6-producing mel-
anoma cells exerted a growth-inhibitory effect on distant 
parental tumors in a dose-dependent manner. The growth of 
HFH18/ IL-6(+) melanomas was also decreased in nude mice, 
suggesting that melanoma-derived IL-6 may mediate this 
anti-tumor effect independently of a normal host B- and 
T-cell immune response. Thus, melanoma-derived IL-6 
exerts a significant inhibitory effect on cutaneous melanoma 
growth and progression. These results indicate that mela-
noma cytokines may have a profound effect on tumor patho-
genesis. Key words: interleukin-6/melanoma/cytokines. ] Invest 
DermatoI102:278-284, 1994 
tion [5]. Prior observations that IL-6 is produced by a number of 
hematopoietic as well as solid neoplasms other than melanomas 
have led to investigations of the role ofIL-6 in tumorigenesis [10-
17]. IL-6 has been shown to have both tumor-promoting as well as 
anti-tumor effects in various types of tumors studied by different 
experimental approaches [13-20]. The importance of specific 
tumor-derived cytokines in the biology of malignant melanoma is 
essentially unknown. In this study we have evaluated the effect of 
tumor-derived IL-6 on the pathogenesis of malignant melanoma in 
an immunocompetent syngeneic murine host. We report here that 
melanoma-derived IL-6 can exert a significant inhibitory effect on 
subcutaneous melanoma growth and progression. 
MATERIALS AND METHODS 
Melanoma Cell Lines The murine B16-derivcd malignant melanoma 
cell lines NP133, HFH18, and HFH(M) obtained from Dr. Funan Hu 
(Oregon Primate Center, Portland, OR) [21,22) were grown and main-
tained in Dulbecco's modified Eagle's medium (DMEM) cell culture media 
(Gibco, Grand Island, NY supplemented with 5% calf serum. Transfected 
HFH18 cells were cultured in selective tissue culture media supplemented 
with 0.8 -1.0 mg/ml geneticin (G418). 
Bioassay for IL-6 Secreted IL-6 activity was measured in the B9 prolifer-
ation bioassay as described previously [5,23,24). Cell proliferation was mea-
sured as a function of incorporated 3H thymidine counts per minute 
([cpm] ± SEM) in triplicate wells at dilutions ranging from 1: 2 to 1: 1260. 
Specificity of this assay was confirmed by inhibiting B9 proliferative activity 
with neutralizing a-murine IL-6 antibody (R&D Systems, Minneapolis, 
MN). 
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Melanoma Cell Proliferation Assays Melanoma cell lines were plated 
at a cell concentration of 2 X 10' cells/well in triplicate wells of 24-well 
plates in DMEM with 1 % calf serum alone, or with lOOI1/m! recombinant 
murine IL-6 (Biosource International, Camarillo, CAl added every 24 h. In 
selected experiments, 10 I1g/m! neutralizing a-murine IL-6 antibody (R & 
D Systems) was added to cultured cells every 48 h. Cells were trypsinized 
and counted with a hemocytometer and Coulter counter at days I, 3, and 6 to 
determine the number of cells per well. 
Northern Blot Analysis RN A was extracted from murine melanoma cell 
lines that were cultured as above [5] . Poly A+ mRNA was prepared by the 
oligo (dT)-cellulose affinity chromatography method as previously de-
scribed [25]. Northern blot analysis was performed as described previously 
[5]. The murine IL-6 cDNA probe used in these studies was generously 
provided by J. van Snick (Brussels, Belgium). Equivalent loading of RNA in 
each lane was confirmed by hybridizing the blots with the cDNA probe for 
the gene cyclophilin (IBIS), which was generously provided by J. Douglas 
(Oregon Health Sciences University, Portland, OR) . 
Transfection of Melanoma Cells The pHPIB5 plasmid containing 
murine IL-6 cDNA was generously provided by J. van Snick (Brussels, 
Belgium). The pZipNeo SV(X) expression vector used in the transfection of 
the HFH18 murine melanoma cell lines was provided by R. Mulligan (Mas-
sachusetts Institute of Technology, Cambridge, MA) [26]. An 1100-base 
pair (bp) Eco Rl fragment of pHPIB5 containing the entire mIL-6 cDNA 
coding sequence was sub cloned into the Bam HI site of pZipNeo SV(X). An 
asymmetric Bgl II restriction site within the Eco Rl insert was used to orient 
the resulting plasmids. Plasmids were then constructed with 1) the murine 
IL-6 cDNA in the 5'-3' orientation for expression ofIL-6 protein and 2) the 
murine IL-6 cDNA in the 3'-5' orientation, which results in no IL-6 protein 
synthesis. These TL-6 plasmids as well as pZipNeo SV(X) vector alone were 
transfected into the non-IL-6 producing HFH18 parental cell line by elec-
troporation. Cells were plated in non-selected media for 48 h, then replated 
in media containing 1 mg/ml G418. Neomycin-resistant clones were iso-
lated with glass cloning rings after 10 -14 d, expanded in cell culture, and 
screened for IL-6 production using the B9 IL-6 bioassay. A clone with the 
IL-6 cDNA in the 5'-3' orientation that secreted significant levels of IL-6 
was designated HFH18/IL-6(+) and a clone with the IL-6 cDNA in the 3'-5' 
orientation that secreted no IL-6 was designated HFH18/IL-6(-) for use in 
further experiments. 
Animals Specific-pathogen-free 6-week-old female C57BL/6 mice or 
athymic C57BL/6 nu/nu (nude) mice were obtained from Jackson Animal 
Laboratories (Bar Harbor, ME) and housed in the animal facilities at the 
Portland Veterans Affairs Medical Center. 
Measurement of Tumor Size and Host Survival Cultured murine 
melanoma cells (NP133, HFH18, HFH(M), or transfected HFH18 cells) 
were trypsinized when cells approached log-phase growth, washed twice in 
phosphate-buffered saline (PBS), and resuspended in PBS for injection. The 
number of viable cells was determined by the trypan blue exclusion method. 
Suspensions of cells in 0.2 ml PBS were inoculated subcutaneously (sc) into 
the anterior flank. Tumor mean diameter was determined by measuring 
tumors of methoxyflurone-anesthetized animals in two perpendicular axes 
with calipers. Tumor volume was determined by measuring tumors in threc 
perpendicular diameters with calipers with tumor volume calculated as t X 
(length X width X height) [27]. Differences in tumor size between groups 
were determined by a two-way analysis of variance. Differences in survival 
between groups were dctermined by life table analysis. 
Histology and Immunohistochemistry Sections of melanoma tissue 
were stained with hematoxylin and eosin (H&E) and examined by light 
microscopy. Immunohistochemistry was performed as previously described 
with melanoma tissue embedded immediately in OCT and frozen at - 80· C 
[28]. Briefly, tissue was cut into 4-11 frozen sections that were fixed in cold 
acetone, stained with monoclonal rat a-murine IL-6 antibody (Pharmingen, 
San Diego, CAl followed by alkaline phosphatase-conjugated rabbit a-rat 
IgG, and color was developed using fast red TR as substrate. Immunohisto-
chemistry was similarly performed on mono layers of cultured melanoma 
cells fixed in actone then permeabilized with 0.1 % saponin [28] using 
monoclonal rat a-murine IL-6 antibody (Pharmingcn) to evaluate IL-6 pro-
duction and monoclonal rat a-murine IL-6 receptor antibody (Bio Source 
International) to evaluate IL-6 receptor expression. 
Peritumoral Administration of Murine a·IL·6 Antibody C57BL/6 
mice (four mice/group) inoculated sc with 1 X 106 HFH18 or HFH18/IL-
6(+) cells received peritumoral injections of 10 I1g of neutralizing monoclo-
nal rat a-murine IL-6 antibody (Pharmingen) every 48 h beginning at day O. 
Control mice received peri tumoral injections of 10 I1g isotype-matched rat 
IgG K antibody (Pharmingen) every 48 h beginning at day O. Tumors were 
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Figure 1. IL-6 secretion by melanoma cell lines. Serial dilutions of 48-h 
supernatants from NP133, HFH18, and HFH18(M) murine melanoma ceU 
line~ wer~ ass~yed for IL-6 bioactivity in the B9 murine plasmacytoma 
prohferatlOn bIoassay. These data arc representative of triplicate experi-
ments. 
measured in three perpendicular axes with calipers at 2-d intervals and tumor 
volume was calculated as above [27] . 
RESULTS 
Heterogeneity of IL-6 Production and Tumorigenicity in 
Murine Melanoma Cell Lines Three B 16-derived murine mel-
anoma cell lines (NP133, HFH18, and HFH(M)) were character-
ized in terms of in vitro IL-6 production and tumorigenicity in 
syngeneic C57BL/6 mice. The secretion ofIL-6 by these cell lines 
was measured in the B9 bioassay (Fig 1). As indicated, the NP133 
cell line constitutively secretes significant amounts of IL-6 bioacti-
vity. In contrast, the HFH18 and HFH(M) cell lines do not secrete 
detectable amounts of IL-6 bioactivity. Parallel differences were 
noted in mRNA levels (data not shown). The ability of NP133, 
HFH18.' and HFJ:1(M) murine melanoma cell lines to generate 
tumors 111 syngeneIc l1uce after subcutaneous inoculation was deter-
mined. Mice ino.culated with the IL-6-secreting NP133 cell line 
develop tumors 111 O!~ly. on~ of 10 treated animals followed up to 
60 d after tumor cell 1I1Jectlon (Table I). In contrast, mice injected 
with the non:-IL-6-secreting HFH18 and HFH(M) cell lines de-
velop .tumors m 100% of treated animals within 15 d post injection. 
The smgle tumor that developed in one animal inoculated with the 
NP133 cell line was approximately one third the size of the HFH18 
or HFH(M) mela~omas at d 30 after injection. These results suggest 
that IL-6 production by murine melanoma cells may be related to 
decreased tumor growth and progression ill vivo. Because other 
tumor cell phenotypic differences could also account for differences 
in me.lanoma tu~origenicity, we generated melanoma cell lines 
that dIffered only m their ability to produce IL-6. 
Table I. Tumorigenicity of Murine Melanoma Cell Lines in 
Syngeneic Mice" 
Melanoma Number of Mice Tumor Mean 
Cell Line Developing Tumors Diameter b Survival 
NP133 1/10 11 .5 mm --, 
HFH(M) 10/10 37.6 ± 10.3 mm 28.4 ± 6.5 d 
HFH18 15/15 22.1 ±4.7 mm 26.9 ± 8.9 d 
• C57BL/6 mice were inoculated sc in the anterior /lank with 1 X 10' murine mela-
noma cells. Tumor growth and host survival were detennined (±SD). 
I Tumor mean diameter was detennined at d 30 after tumor cell injection or at the 
time of death if before d 30. 
, All mice were alive at 60 d after tumor cell inoculation. 
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Figure 2. IL-6 secretion by transfected melanoma cell lines. Serial dilutions 
of 48-h supernatants from HFH18, HFH18/IL-6(+), HFH18/IL-6(-), and 
HFH 18/neo melanoma cell lines were assayed for IL-6 bioactivity in the B9 
murine plasmacytoma proliferation bioassay. These data are representative 
of triplicate experiments. 
Establishment of IL-6-Producing Melanoma Cell Lines 
Genetically identical melanoma cell lines that differed only in IL-6 
production were established. A murine IL-6 eDNA expression vec-
tor was transfected into the non-IL-6 - producing HFH18 mela-
noma cell line. A transfected clone designated HFHI8/IL-6(+) was 
found to constitutively secrete high levels ofIL-6 as determined in 
the B9 IL-6 bioassay and thus was selected for further in vivo studies 
(Fig 2) . Parental HFH18 cells transfected with the pZipNeoSV 
vector alone (HFHI8/neo) or with the IL-6 eDNA gene insert in 
the reverse (3'-5') orientation (HFH 18/IL-6(-») did not secrete IL-6 
(Fig 2) . The production ofIL-6 by the HFH18/IL-6(+) cell line was 
confirmed by immunohistochemistry (data not shown) . The prolif-
eration rate of cultured IL-6-producing melanoma cells does not 
differ significantly from that of the parental HFH18 cell line or the 
HFHI8/IL-6(-) line. Additionally, the in vitro proliferation of the 
parental cell line i.s not a.ffec~ed by t?e ad.dition of recombinant 
murine IL-6 nor IS the In vitro proliferation of the transfected 
HFHI8/IL-6(+) cell line altered by the addition of neutralizing 0' 
murine IL-6 antibody to the cultured cells (data not shown). Similar 
levels of IL-6 receptors are observed in HFH 18 parental, HFH 18/ 
IL-6(+), HFHI8/IL-6(-), and NP133 cell monolayers by immuno-
histochemistry (data not shown). These data indicate that tumor cell 
growth is not directly altered in vitro by the transfection process 
itself or by IL-6. 
Transfection of the IL-6 Gene into Melanoma Cells Results 
in Decreased Tumor Growth and Improved Host Survival 
Mice inoculated with either the HFH 18 parental melanoma cells or 
HFHI8/IL-6(-) cells develop tumors that reach a final mean tumor 
diameter of approximately 25 mm by d 30 (Fig 3). ~n ~ontrast, 
animals inoculated with HFH18/IL-6(+) cells develop slgmficantly 
smaller tumors with a final mean tumor diameter of only 12 mm by 
d 30 (p < 0.001; HFHI8/IL-6(+) versus HFH18 or HFH18/IL-
6(-») . Tumor development in mice injected with HFH18/neo cells 
parallels the growth of the HFH18 line itself (data not shown). The 
consequence of IL-6 secretion by HFH18 melanoma cells on host 
survival is summarized in Fig 4. Mice injected with the parental 
HFH18 cell line or the HFHI8/IL-6(-) cell line have a median 
survival of25 d. In contrast, mice injected with the HFH18/IL-6(+) 
cell line have a significant increase in survival with a median sur-
vival time of 55 d (p < 0.001 ; HFH18/IL-6(+) versus HFH18 or 
HFH18/IL-6(- ») . Thus, IL-6 secretion by the HFH18 murine mela-
noma cell line results in decreased tumor growth and increased 
survival of the recipient mice. 
IL-6 Production ofHFH18/IL-6(+) Melanomas The produc-
tion of IL-6 was compared by immunohistochemistry in tumors 
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Figure 3. Effect of IL-6 transfection on the growth of subcutaneous mela-
nomas. The growth of tumors in groups of Cs7BL/6 mice (10 animals/cell 
line/time point) inoculated sc with 1 X 106 HFH18 parental (e), HFH18/ 
IL-6(-) (.A.), or HFH18/IL-6(+) (II) melanoma cells was measured at d 5,10, 
15, and 30 after tumor cell inoculation. Tumor mean diameter was deter-
mined as ! (tumor length X width) and SO is indicated by error bars. 
that developed in animals injected with NP133 cells, HFH18 cells, 
and HFH18 transfected melanoma cells. HFH18/IL-6(+) tumors 
stain strongly positive for IL-6 (Fig SA) . In contrast, little IL-6 
staining is detected in HFH18 (Fig 5B) or HFH18/IL-6(-) tumors 
(data not shown) . As a positive control, NP133 tumors that consti-
tutively produce IL-6 in vitro also stain strongly positive for IL-6 
(Fig 5C). HFHI8/IL-6(+) tumor explants continue to secrete IL-6 
bioactivity in tissue culture whereas HFH18 or HFH18/IL-6(-) 
tumor explants secrete no IL-6 bioactivity in culture (data not 
shown) . These studies indicate that tumors that develop from in-
jected HFH18/IL-6(+) cells continue to secrete IL-6 in vivo. 
Elevated Serum IL-6 in Mice Bearing HFH18/ IL-6(+) 
Tumors To determine whether local tumor production of IL-6 
results in increased serum levels of this cytokine, serum IL-6 levels 
in mice inoculated with either the HFH18 melanoma cell line or 
the HFH18 transfected cell lines were measured in the B9 bioassay. 
As indicated in Fig 6, serum IL-6levels of mice developing tumors 
after injection with HFH18 and HFHI8/IL-6(-) cells are similar to 
those of mice injected with saline at 5,10, and 15 d after tumor cell 
injection (Fig 6). In contrast, serum IL-6 levels in mice developing 
tumors after inoculation with HFH18/IL-6(+) cells are markedly 
elevated above control levels by d 15 and continued to increase up to 
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Figure 4. Effect of melanoma IL-6 production on animal survival. Cs7BL/ 
6 mice (10 mice/group) were inoculated sc with 1 X 106 HFH18 parental 
(e), HFH18/IL-6(-) (.A.), or HFH18/IL-6(+) (II) melanoma cells and fol-
lowed until death. 
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Figure 5. Immunohistochemical detection of IL-6 in excised melanoma 
tissue. Tumor tissue was obtained at d 15 from C57BLj6 mice inoculated sc 
with 1 X 106 HFH18jIL-6(+) melanoma cells (A), HFH18 parental mela-
noma cells (B), or NP133 murine melanoma cells as a positive control 
(C). Immunohistochemistry was performed using a primary monoclonal rat 
a-murine IL-6 antibody. The controls were tumor tissue treated with rat 
IgG and tissue treated with secondary antibody only (data not shown). Bar, 
10,um. 
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Figure 6. Serum IL-6 levels in melanoma-bearing mice. Groups of 
C57BLj6 mice were inoculated sc with 1 X 106 HFH18 parental (e), 
HFH18jIL-6(-) ("'), or HFH18jIL-6(+) (II) cells. Control mice were in-
jected sc with saline alone at day 0 (0). Serum samples were obtained when 
mice were euthanized at 5,10, 15, and 30 d after tumor cell injection. Serum 
IL-6 ~ioactivity was determined by the B9 murine plasmacytoma prolifera-
tion blOassay. These data are the average of serum samples from four animals 
per cell line injected at each time point expressed as unitsjml, with SD 
indicated by error bars. 
d 30 after tumor cell inoculation (Fig 6). Interestingly, by d 3D, the 
serum IL-6levels of mice bearing HFH18 or HFH18/IL-6(-) mela-
nomas are also elevated above control animal levels. At this stage the 
tumor weight of these non - IL-6 - producing tumors is approxi-
mately 50% of the weight of the mouse. Increased serum IL-6levels 
with a large tumor cell burden have been previously reported in 
various types of neoplasms [29,30]. The tumor burden of mice bear-
ing small HFH18/IL-6(+) tumors is significantly less than that of 
mice bearing the significantly larger HFH18 parental or HFH18/ 
IL-6(-) melanomas at all time points after tumor cell inoculation. In 
spite of this small tumor size, however, these neoplasms are asso-
ciated with high levels of serum IL-6. These results indicate that the 
mice with HFH18/IL-6(+) melanomas have significantly higher 
levels of serum IL-6 compared to animals with HFH18 or HFH18/ 
IL-6(-) melanomas (p < 0.01) . 
Histologic Examination of Melanomas Injected HFH18 and 
HFH18/IL-6H tumor cells develop into large, poorly circum-
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Figure 7. Systemic anti-tumor effect of melanoma-derived IL-6. Groups of 
C57BLj6 mice (five mice/group) were injected sc with 1 X 106 HFH18 
parental cells in each flank (A); 1 X 106 HFH18 parental cells in one flank 
and 1 X 106 HFH18jIL-6(+) cells in the opposite flank (B); or 1 X 106 
HFH18 parental cells in one flank and 5 X lOs HFH18jIL-6(+) cells in the 
opposite flank (C). Data are represented as weight of unilateral HFH18 
parental tumors at d 30 with SD indicated by error bars. 
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Figure 8. IL-6 inhibition of melanoma growth is reversed by injection of 
peritumoral a-IL-6 antibody. Groups of C57BL/6 mice were inoculated sc 
with 1 X 106 HFH18 parental or HFH18/IL-6(+) melanoma cells. Experi-
mental mice in each group received peritumoral injections of 10 Jig of 
neutralizing monoclonal rat a-murine IL-6 antibody every 48 h for 30 d. 
Control mice received peritumoral injections of 10 Jig of rat IgG K isotype 
standard antibody every 48 h beginning at d O. Data are represented as tumor 
volume at d 30 with SD indicated by error bars. 
scribed neoplasms by d 10. In contrast, the small tumors formed by 
the HFH18/IL-6(+) cell line are sharply circumscribed and have no 
evidence of an infiltrative tumor cell pattern. Both IL-6 - producing 
and non - IL-6 - producing melanomas are associated with a moder-
ately dense peritumoral inflammatory cell infiltrate composed pri-
marily of lymphocytic cells as determined by light microscopy of 
H&E-stained sections. 
Systemic Anti-tumor Effect of Melanoma-Derived IL-6 To 
determine whether HFH18/IL-6(+) melanomas inhibit the growth 
of HFH18 melanoma cells at a distant site, mice were inoculated sc 
with both cell rypes at separate sites and tumor weight was measured 
at d 30 post injection. Mice co-injected with equal numbers of 
HFH18 cells (1 X 106) in one flank and HFH18/IL-6(+) in the 
opposite flank demonstrate a 40% decrease in the weight ofHFH18 
tumors compared to HFH18 tumors in control animals (Fig 7). 
Mice co-injected with 1 X 106 HFH18 cells in one flank and half as 
many HFH18/IL-6(+) cells (5 X 105) in the opposite flank develop 
HFH18 tumors that are only slightly decreased in size compared to 
controls. Thus, IL-6 produced by the HFH18/IL-6(+) melanoma 
cells exerts a systemic growth-inhibitory effect on the growth of 
distant parental tumors in a dose-dependent manner. 
IL-6 Inhibition of Melanoma Growth is Reversed by Injec-
tion of Peri tumoral a-IL-6 Antibody To confirm the speci-
ficity of the apparent IL-6 - mediated inhibition of melanoma 
growth, mice were inoculated sc with either the HFH18 cell line or 
the IL-6-producing HFH18/IL-6(+) cell line and peritumoral in-
jections of 10 fig a-murine IL-6 antibody were administered every 
48 h. The treatment ofHFH18 tumors with a-mIL-6 antibody has 
no effect on tumor volume at d 30 (Fig 8). In contrast, the treatment 
of IL-6 - secreting HFH 18 /IL-6(+) tumors with a-mIL-6 antibody 
results in tumors that grow to the same size as the parental HFH18 
cell line at d 30. The control isotype-matched rat immunoglobulin 
(lg)G administered peritumorally every 48 h has no effect on tumor 
growth. The augmented growth of the HFH18/IL-6(+) tumors by 
local injection of neutralizing a-IL-6 antibody provides further evi-
dence that IL-6 is responsible for the decreased it) vivo growth of 
these melanomas. 
Growth of Murine Melanomas in Nude Mice Our studies 
indicate that IL-6 does not have an apparent direct in vitro inhibitory 
effect on melanoma cell growth. The observed decrease in in vivo 
melanoma growth may be mediated by IL-6 through other mecha-
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Figure 9. Growth of murine melanomas in nude mice. Groups of four 
athymic nu/nu (nude) mice were inoculated sc with 1 X 106 HFH18 paren-
tal (e), HFH18/1L-6(- ) (.), or HFH18/IL-6(+) (II) melanoma cells. Tumor 
size measured at 4-d intervals is depicted as tumor volume [volume = 
(length X width X height)/2] with SD indicated by error bars. 
nisms such as the induction of other inhibitory cytokine(s) or of 
anti-tumor immune cell subsets. To begin to address this issue, nude 
mice were injected with HFH18 and HFH18/IL-6H cells. These 
animals develop tumors that steadily progress in size to a mean 
tumor of approximately 4050 mm3 by d 32 (Fig 9). In contrast, 
nude mice injected with the HFHI8/IL-6(+) cell line develop sc 
tumors that reach a mean tumor volume of only 2000 mm3 by d 32 
(Figs 9, 10). Thus, the anti-tumor effect mediated by melanoma-
derived IL-6 appears not to be dependent on a normal host B- and 
T-cell immune response. 
DISCUSSION 
Previous studies indicate that there is significant heterogeneity in 
the cytokine production profile of malignant melanomas [5,9]. 
Using a well controlled animal model, we tested the hypothesis that 
a specific tumor-derived cytokine may have a profound effect on the 
growth and progression of cutaneous melanomas. We found that 
melanoma-derived IL-6 exerts a significant inhibitory effect on sub-
cutaneous melanoma growth and progression. This is consistent 
with our observation of an inverse relationship between IL-6 pro-
duction of three B 16-derived murine melanoma cells lines (NP 133, 
HFHI8, and HFH(M)) and the tumorigenicity of these melanoma 
cells in syngeneic mice. 
IL-6 is a pleotropic cytokine with a wide variety of inflammatory 
properties. These include the activation ofB and T cells, induction 
of immunoglobulin production, stimulation of hepatocytes to pro-
duce acute phase proteins, and the proliferation of hematopoietic 
progenitor cells [31-35]. Additionally, IL-6 activates natural killer 
(NK) cells [36] and human lymphokine-activated killer (LAK) cells 
[37), and serves as a cytotoxic lymphocyte (CTL) differentiation 
factor [38]. 
The role of IL-6 in neoplasia has been the topic of a number of 
recent reports. IL-6 production has been reported to occur in several 
different types of malignant human cells including cardiac myxo-
mas, bladder carcinomas, and epidermoid carcinoma cell lines 
[10,11]. We have shown that human melanoma cell lines produce 
IL-6 and that there are distinct differences in the IL-6 production 
between two human metastatic melanoma cell lines tested [5]. One 
melanoma cell line constitutively expresses IL-6 mRNA and se-
cretes IL-6 activity, whereas the other cell line does not produce a 
significant amount of IL-6. In another recent study, it was also 
noted that one of two human melanoma cell lines tested did not 
constitutively produce IL-6, but did secrete IL-6 after induction 
with rIL-la [6J. There is evidence to support both tumor-promot-
ing and tumor-inhibitory properties of IL-6, which may depend 
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Figure 10. Growth of murine melanomas in nude mice. Groups of nude 
mice were inoculated sc with 1 X 106 HFH18/IL-6(+) cells (A) or HFH18 
parental cells (B). These photographs are representative of four mice injected 
with each cell type evaluated at the 30-d tIme pomt. 
both on the tumor cell type and inherent limitations of experimen-
tal approaches used [13 - 20, 39 - 41]. 
The role oflL-6 in the biologic behavior of malignant melanoma 
has been evaluated from different experimental approaches. R:ecent 
studies have begun to evaluate the effect ofIL-6 on melanocytic cell 
proliferation. IL-6 is reported to suppress the proliferation of cul-
tured neonatal human melanocytes [42]. Kerbel and co-workers 
have reported that IL-6 acts as an inhibitory growth factor for mela-
noma cells removed from lesions of radial growth phase or early 
vertical growth phase (non-metastatic) melanoma cells, where~s 
melanoma cell lines from advanced stage cutaneous or metastatic 
lesions were resistant to this inhibitory effect [8]' In another recent 
study, Morinaga et al demonstrated that IL-6 could inhibi~ the in 
vitro proliferation of an IL-6-producing melanoma cell lme [6]. 
These results suggested that IL-6 may function as an autocrine anti-
proliferative factor for c.ert~i~ ~elanoma cells [6]. However, in ?ur 
studies, we observe no mhlbltlOn of the parental HFH18 cellll11e 
proliferation in vitro by exogenous murine IL-6. The decreased in 
vivo growth of transfected, IL-6-producing melanoma cells may 
thus reflect function(s) ofIL-6 other than direct inhibition of mela-
noma cell proliferation. 
Another recent study also has utilized IL-6 gene transfection to 
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evaluate melanoma growth in mice [43]. Sun et al have demon-
strated decreased tumor growth in Vill O by B16 melanoma cells 
transfected with the human IL-6 gene [43]. Additionally, the sc 
growth of non-transfected B 16 cells was reduced in animals receiv-
ing daily sc injections of human recombinant IL-6 (5 /lg/d). In tllls 
study, subcutaneous tumor growth was evaluated only between d 10 
and 17 whereas our studies evaluated tumor size between d 0 and 30, 
and we evaluated survival in separate groups of mice to allow us to 
evaluate the entire course of melanoma growth. Also, Sun et al noted 
the IL-6 - transfected melanoma cells formed tumors with distinct 
histologic featu.res including a prominent stromal matrix, infiltra-
tion of inflammatory cells, and fewer blood vessels, whereas no 
similar histologic changes were noted in our study. This difference 
could be related to their use of the human IL-6 gene in a murine 
system whereas we used a murine IL-6 gene in murine tumor cells. 
The authors speculate that IL-6 may mediate this antitumor re-
sponse by nonspecific pro inflammatory mechanisms. This study is 
in agreement with our findings that IL-6 exerts an anti-melanoma 
effect in vivo. In addition, we demonstrate that this effect apparently 
does not require an intact T - and B-cell immunologic system. 
Our studies indicate that serum IL-6 levels in mice bearing 
HFH18/IL-6(+) cells were significantly higher than in mice bearing 
HFH18 parental or HFH18/IL-6(-) tumors even though actual 
tumor burden was much less in these animals. An increase in serum 
IL-6 with a large tumor cell burden has been previously reported in 
various types of neoplasms [29,30]. The tumor burden of mice bear-
ing HFH18/IL-6(+) tumors was significantly less than that of mice 
bearing HFH18 parental or HFH18/IL-6(-) melanomas at all time 
points after tumor cell inoculation. These results indicate that the 
mice injected with HFH18/IL-6(+) melanoma cells have signifi-
cantly higher levels of serum IL-6 compared to control animals. It is 
likely that IL-6 production by the injected HFH18/IL-6(+) cells was 
primarily responsible for the elevated serum IL-6 levels in these 
mice. 
Thus, we have demonstrated that IL-6 production results in de-
creased growth and progression of sc malignant melanoma. This 
provides further evidence for the role of this multifunctional cyto-
kine in the biology of this neoplasm. The experimental model de-
veloped in this study facilitates the evaluation of the complex auto-
crine, paracrine, and systemic effects of melanoma cell-derived 
cytokines in melanoma pathogenesis. Experiments are under way to 
further evaluate the mechanism by which IL-6 exerts this in vivo 
effect. The heterogeneity of cytokine production by human malig-
nant melanomas, however, suggests the need to evaluate additional 
cytokines or combinations of cytokines using an in vivo model. 
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